{"title":"Markers of Endotoxemia and Inflammation are Associated with Digital Ulcers in Systemic Sclerosis Patients.","authors":"Chiara Pellicano, Alessandra Oliva, Amalia Colalillo, Cristina Luceri, Antonietta Gigante, Claudio Maria Mastroianni, Daniela Tornese, Valeria Carnazzo, Valerio Basile, Edoardo Rosato, Umberto Basile","doi":"10.1080/08820139.2025.2478932","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the possible role of lipopolysaccharide-binding protein (LBP) and interleukin 6 (IL-6) in the development of digital ulcers (DUs) in Systemic sclerosis (SSc).</p><p><strong>Methods: </strong>60 SSc patients were enrolled and tested for serum levels of LBP and IL-6. The development of DUs was assessed in a 12-month follow-up period.</p><p><strong>Results: </strong>Median LBP and IL-6 were 107.445 ng/mL and 10.8 pg/mL whilst 33.3% patients had LBP ≥ 11995 ng/mL and 51.7% patients had IL-6 ≥ 12.5 pg/mL. DUs history were present in 41.7% SSc patients and at follow-up 23.3% patients developed new DUs. Baseline LBP (14105 ng/mL vs 10355 ng/mL, <i>p</i> < .001) and IL-6 (195 pg/mL vs 9.4 ng/mL, <i>p</i> < .001) were higher in SSc patients with new DUs. The ROC curves showed a good diagnostic accuracy for a cut-off of LBP ≥ 11995 ng/mL [AUC = 0.804 (95% CI = 0.656-0.951), <i>p</i> < .001] and for a cut-off of IL-6 ≥ 12.5 pg/mL [AUC = 0.897 (95% CI = 0.783-1.000), <i>p</i> < .001]. Free survival from new DUs was shorter in SSc patients with increased LBP (<i>p</i> < .001) or IL-6 (<i>p</i> = .003).</p><p><strong>Conclusions: </strong>LPB or IL-6 could play a role in digital microvascular damage of SSc patients.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"1-14"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820139.2025.2478932","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The aim of this study was to evaluate the possible role of lipopolysaccharide-binding protein (LBP) and interleukin 6 (IL-6) in the development of digital ulcers (DUs) in Systemic sclerosis (SSc).
Methods: 60 SSc patients were enrolled and tested for serum levels of LBP and IL-6. The development of DUs was assessed in a 12-month follow-up period.
Results: Median LBP and IL-6 were 107.445 ng/mL and 10.8 pg/mL whilst 33.3% patients had LBP ≥ 11995 ng/mL and 51.7% patients had IL-6 ≥ 12.5 pg/mL. DUs history were present in 41.7% SSc patients and at follow-up 23.3% patients developed new DUs. Baseline LBP (14105 ng/mL vs 10355 ng/mL, p < .001) and IL-6 (195 pg/mL vs 9.4 ng/mL, p < .001) were higher in SSc patients with new DUs. The ROC curves showed a good diagnostic accuracy for a cut-off of LBP ≥ 11995 ng/mL [AUC = 0.804 (95% CI = 0.656-0.951), p < .001] and for a cut-off of IL-6 ≥ 12.5 pg/mL [AUC = 0.897 (95% CI = 0.783-1.000), p < .001]. Free survival from new DUs was shorter in SSc patients with increased LBP (p < .001) or IL-6 (p = .003).
Conclusions: LPB or IL-6 could play a role in digital microvascular damage of SSc patients.
背景:本研究的目的是评估脂多糖结合蛋白(LBP)和白细胞介素6 (IL-6)在系统性硬化症(SSc)患者数字溃疡(DUs)发展中的可能作用。方法:选取60例SSc患者,检测血清LBP和IL-6水平。在12个月的随访期间评估DUs的发展情况。结果:中位LBP和IL-6分别为107.445 ng/mL和10.8 pg/mL, 33.3%的患者LBP≥11995 ng/mL, 51.7%的患者IL-6≥12.5 pg/mL。41.7%的SSc患者有DUs病史,随访时23.3%的患者出现新的DUs。基线LBP (14105 ng/mL vs 10355 ng/mL, p p p p p = 0.003)。结论:LPB或IL-6可能在SSc患者手指微血管损伤中起一定作用。
期刊介绍:
Disseminating immunological developments on a worldwide basis, Immunological Investigations encompasses all facets of fundamental and applied immunology, including immunohematology and the study of allergies. This journal provides information presented in the form of original research articles and book reviews, giving a truly in-depth examination of the latest advances in molecular and cellular immunology.